相关实验视频
Updated: Jan 16, 2026

Histological Analyses of Acute Alcoholic Liver Injury in Zebrafish
Published on: May 25, 2017
与酒精相关的肝病患者的Resolvin D1值
İrfan Küçük1, Musa Salmanoğlu2, Süleyman Baş3
1Department of Gastroenterology, University of Health Sciences, Kartal Dr. Lütfi Kırdar City Hospital, İstanbul, Turkey. drirfn@gmail.com.
在严重的酒精相关性肝病 (ALD) 中,血清Resolvin D1 (RvD1) 水平较低. 较低的RvD1表明更严重的肝损伤,并可能作为潜在的非侵入性生物标志物用于ALD进展.
科学领域:
- 脂质媒介研究的研究.
- 肝病学 肝病学是一种肝病学.
- 发现生物标志物的发现.
背景情况:
- 在酒精相关肝病 (ALD) 模型中,Resolvin D1 (RvD1) 与肝损伤有关.
- 这项研究调查了血清RvD1水平与ALD临床表现之间的关联.
研究的目的:
- 评估与酒精相关性肝病 (ALD) 患者血清RvD1水平和临床表型之间的关系.
主要方法:
- 一项涉及82名ALD患者和48名健康对照者的病例控制研究.
- ALD患者被分组为与酒精相关的脂肪性肝 (ASL),与酒精相关的肝炎 (AH) 和与酒精相关的肝硬化 (AC).
- 使用ELISA量化血清RvD1水平,并对肝纤维化 (Fib-4),MELD-Na得分,Child-Pugh分类和Maddrey分辨功能进行评估.
主要成果:
- 与ASL和HC组相比,AH和AC组的血清RvD1水平明显较低 (p < 0.001).
- 在肝硬化组中,较低的RvD1水平与,食道/胃静脉,以及先进的Child-Pugh类相关.
- 在AC组中,RvD1水平与Fib-4,MELD-Na和Child-Pugh分数呈反向相关性.
结论:
- 血清RvD1水平与与酒精相关的肝病严重程度相关.
- RvD1显示出作为ALD的非侵入性生物标志物的潜力.
- 需要在独立队列中进一步验证,以确认RvD1在ALD中的临床实用性.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Hepatic Drug Excretion: Influencing Factors
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Liver Physiology
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...

